American Thoracic Society International Conference

In this interview at ATS 2025, Arthur Reingold, MD, highlights the role of pulmonologists and other health care providers in combatting vaccine misinformation.

Marchetti explains the benefits of assessing RV/TLC rather than absolute RV to determine the efficacy of BLVR in patients with emphysema and hyperinflation.

This analysis highlights rademikibart’s effect on blood eosinophil counts in those with asthma, exploring whether there was an IL-4Rα class effect.

This interview at ATS 2025 highlights the talk given by Grace Lee, MD, MPH, regarding the policy side of public health concerns over widespread immunization.

A post-hoc analysis of SURMOUNT-OSA highlights tirzepatide’s consistent benefit across all baseline OSA severity groups.

The FIBRONEER-IPF and FIBRONEER-ILD data highlight nerandomilast’s efficacy and safety in idiopathic pulmonary fibrosis and progressive pulmonary fibrosis.

This analysis highlights the rapid improvements seen in patients with uncontrolled asthma within 24 hours of their initial rademikibart dose.

The pooled analysis of ENHANCE clinical trial program data highlight improvements in HRQoL, dyspnea, and COPD symptoms with ensifentrine monotherapy.

Nearly all treated patients received glucocorticoids, but many quickly needed later-line therapies, especially those with non-incident pulmonary sarcoidosis.

The ProVENT data highlight dupilumab’s efficacy in treating severe asthma, with improvements in control, quality of life, and exacerbations being observed.

Phase 3 BATURA data reveal a 47% reduction in the risk of severe exacerbations in mild asthma with albuterol/budesonide (Airsupra) versus albuterol alone.

In this analysis, investigators found consistent benefits over placebo among children with type 2 asthma treated with dupilumab, regardless of condition length.

In this ATS 2025 interview, Arthur Reingold, MD, was asked about the effects of the COVID-19 pandemic on immunization rates as well as pulmonologists’ role.

These data from ATS 2025 point to climate change as a potential influence on the burden associated with obstructive sleep apnea (OSA).

Pande explains findings from his research on immunosuppression in interstitial lung disease suggesting this treatment does not affect fibrosis progression.

Over 60% of patients admitted to the ICU with ARF experienced some degree of sleep disturbance after admission.

In this interview at ATS 2025, Reingold highlighted his presentation on the global immunization divide and overcoming barriers to universal vaccine coverage.

These data, presented at ATS 2025, highlight the efficacy results of methotrexate when compared to prednisone for pulmonary sarcoidosis.

New research sheds light on improved waitlist outcomes after new allocation guidelines for lung transplants prioritizing medical urgency were implemented.

View slated interviews with experts and 7 clinical trials to watch at ATS 2025.

These late-breaking data on drug candidate ENV-101 were presented at ATS 2024 and resulted from a new study on the drug’s effect on individuals with IPF.

Use of dupilumab reduced exacerbations and improved lung function in COPD patients with type 2 inflammation.

"Our research is unique in its attempt to describe a high-need, high-cost patient population who might benefit from increased monitoring or intervention," Dr. Ann Cameron says.

Criner and colleagues concluded that the 5-year results from the EMPROVE trial demonstrated that Spiration Valve System (SVS) treatment was safe and durable, effectively improving lung function in patients with emphysema

"High-risk patients are more likely to experience comorbid conditions and are more likely to use COPD medications and oxygen, reflecting a higher disease burden," Dr. Ann Cameron explains.

“We all know that exacerbations are the most costly disease impact of COPD,” study investigator Dr. Charlie Strange says.

Dr. Jean-Pierre Llanos Ackert and Dr. Chris Ambrose discuss the latest data on the breakthrough biologic for severe asthma.

Investigators Dr. Jean-Pierre Llanos Ackert and Dr. Chris Ambrose share insight on the efficacy of tezepelumab in severe, uncontrolled asthma, and baseline predictors of enhanced response which support tezepelumab as a promising biologic treatment option.

Late-breaking data validates the FDA clearance of Cytovale's IntelliSep test, demonstrating its potential to aid in the early detection of sepsis in US emergency departments, with the aim of improving patient outcomes.

Late-breaking data from ATS 2023 show new positive evidence of the innovative in-vitro diagnostic tool IntelliSep test that measures the viscoelastic properties of leukocytes, showing promising results for rapid sepsis diagnosis in EDs.